---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-323841"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2026-07-29T20:30:15+00:00"
generated_at: "2026-07-29T20:31:29.687751+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amarin Q2 2026 net revenue $42.2M (-42% YoY); operating loss narrows to $12.0M; cash grows to $314.6M

## Summary
- Total net revenue $42.2M, down 42% YoY due to absence of $25M Recordati upfront payment and generic pressure on U.S. VASCEPA pricing.
- Operating expenses fell 59% to $27.0M; excluding restructuring, down 38% YoY, completing $70M annual cost savings initiative.
- Operating loss improved to $12.0M from $16.0M; net loss $7.7M vs $14.1M; cash grew to $314.6M, debt-free.
- Global in-market demand for VASCEPA/VAZKEPA rose 59% YoY; U.S. IPE market share increased to 48% from 43%.
- Company expects continued international growth, consistent U.S. volumes, and ~10% cash growth by year-end 2026.

## SEC filing metadata
- accession: 0001193125-26-323841
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2026-07-29T20:30:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000119312526323841/0001193125-26-323841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000119312526323841/amrn-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-323841
- JSON: https://secwatch.observer/filing/0001193125-26-323841.json
- Plain text: https://secwatch.observer/filing/0001193125-26-323841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.